PT - JOURNAL ARTICLE AU - Yang, Deng-Ho AU - Chen, Hsiang-Cheng TI - FRI0531 THE ARTICULAR PROTECTION EFFECT OF ISORHAMNETIN IN THE RATS OF MONOSODIUM IODOACETATE-INDUCED OSTEOARTHRITIS AID - 10.1136/annrheumdis-2019-eular.7021 DP - 2019 Jun 01 TA - Annals of the Rheumatic Diseases PG - 959--960 VI - 78 IP - Suppl 2 4099 - http://ard.bmj.com/content/78/Suppl_2/959.3.short 4100 - http://ard.bmj.com/content/78/Suppl_2/959.3.full SO - Ann Rheum Dis2019 Jun 01; 78 AB - Background Osteoarthritis (OA) is a degenerative joint disease with damage to the articular cartilage. Active production of inflammatory cytokine/chemokine and matrix metalloproteinases may be found during the progression of OA. Isorhamnetin had the effects of anti-inflammatory, antioxidant, anti-ischemia, anti-atherosclerotic hepatoprotective and anticancer activities.Objectives Our study was focused on the effects of isorhamnetin treatment in OA.Methods We used monosodium iodoacetate (MIA)-induced OA rats to evaluate the effects of isorhamnetin related anti-inflammatory process. The rats in all groups were sacrificed on four weeks post-MIA injection. The measurements of knee joint swelling, histological analysis, serum inflammatory biomarkers and Western blot were evaluated.Results We found that isorhamnetin may reduce MIA-induced knee swelling by significantly reduction of articular cartilage damage in rats. The severity of OA lesion was graded using the modified Mankin scoring system, and we found that the overall modified Mankin’s scores were significantly decreased after isorhamnetin treatment compared with a MIA-treated group. The production of IL-1β, IL-6, and TNF-α decreased in isorhamnetin treatment group compared with MIA alone group. Isorhamnetin inhibited the production of NO and PGE2, and the expression of iNOS and COX-2. The production of COMP and CTX-II were also inhibited in MIA-induced OA rats.Conclusion Isorhamnetin may modulate the inflammatory progression of OA in MIA-induced OA rats. The prevention of cartilage damage was found in OA after adequate isorhamnetin treatment. Isorhamnetin may serve as a potential agent for the management of OA.References [1] Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol2010; 6: 625-635.[2] Manu KA, Shanmugam MK, Ramachandran L, et al. Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of NF-kappaB signaling cascade in gastric cancer. Cancer Lett2015; 363: 28-36.[3] Chen TL, Zhu GL, Wang JA, et al. Protective effects of isorhamnetin on apoptosis and inflammation in TNF-alpha-induced HUVECs injury. Int J Clin Exp Pathol2015; 8: 2311-2320.Disclosure of Interests None declared